PEGS Europe, Lissabon, Portugal – November 2-6, 2015
November 2-4, Munich, Germany – Partnering
October 26-29, Boston, USA
Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology
Aragen Bioscience, Inc. (Aragen) announces that it has entered into an agreement with ProteoNic Biotechnology BV (ProteoNic) for the commercial use of ProteoNic’s 2G UNic™ recombinant protein production technology. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods. In combination with the value added services offered by Aragen, access to the technology will allow Aragen’s clients to increase manufacturing efficiency and reduce cost of goods for recombinant biologicals.